Sector News

Medtronic to Acquire RF Surgical for $235 Million

July 15, 2015
Life sciences
Medtronic PLC agreed to acquire RF Surgical Systems Inc. for roughly $235 million, the latest in a string of smaller deals since the medical-device maker’s acquisition of Covidien.
 
Carlsbad, Calif.-based RF Surgical makes products that focus on counting items used during surgery—such as surgical sponges, gauze or towels—to help prevent them from being left in the patient during surgery, which can lead to serious complications.
 
RF Surgical’s system uses a low radio frequency signal to track and detect surgical gauze, sponges and towels, which are embedded with an RF tag, through blood, dense tissue and bone.
 
The deal, expected to close next month, is expected to meet Medtronic’s long-term financial metrics for acquisitions, though the deal’s effect on yearly earnings isn’t expected to be material.
 
Medtronic last month agreed to acquire privately held medical-device company Aptus Endosystems Inc. for roughly $110 million and cardiac-mapping company CardioInsight Technologies Inc. in a deal valued at $93 million.
 
Also in June, Medtronic reported a net loss of $1 million in its first combined quarter with Covidien, largely because of $880 million in charges for the Covidien acquisition and a $329 million expense from the resolution of a tax dispute with the Internal Revenue Service.
 
By Tess Stynes
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach